The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Activation of Src kinase in primary colorectal carcinoma: An indicator of poor clinical prognosis
Open accessAbstract
BACKGROUND: The specific activity of the non‐receptor protein tyrosine kinase, Src, is increased in the majority of colon and rectal adenocarcinomas compared to normal mucosa. However, the prognostic significance of this difference is unknown. The objective of the current study was to determine if Src activity is a marker for poor clinical prognosis in colon carcinoma patients. As Src activation leads to expression of urokinase/plasminogen activator receptor (u‐PAR), expression of Src and u‐PAR were correlated with patient survival. METHODS: Tumors and adjacent normal colonic mucosae from 45 patients with colorectal carcinoma were screened for Src activity by the immune complex kinase assay. Expression of u‐PAR was determined by enzyme linked immunoabsorbent assay. The primary tumor‐to‐normal mucosa ratios of activity were compared following classification and regression tree (CART) analysis to determine the prognostic significance of elevated specific Src activity. Expression of u‐PAR was correlated with Src activity. RESULTS: By CART analysis, Src activity in tumors elevated more than twofold over normal mucosa was significant. Increased Src activity significantly correlated with Dukes stage, pT and pN classification, and increased u‐PAR levels (P < 0.001). Kaplan Meier analysis showed a significant association between elevated Src activity and shorter overall survival of all patients (P = 0.0004) and of Dukes Stage A‐C patients (P = 0.0037). In patients who underwent curative resection, a significant correlation with a decreased disease‐free survival rate was found (P < 0.0001). Multivariate analysis revealed that elevated Src activity was a prognostic parameter independent of M classification (P = 0.0125, relative risk 3.54, 95% confidence interval 1.31 – 9.76). CONCLUSIONS: Src activity is an independent indicator of poor clinical prognosis in all stages of human colon carcinoma. These data suggest that Src‐specific inhibitors may have a therapeutic role in inhibiting tumor progression and metastasis, and that measurement of Src activity may aid in selection of early stage patients for adjuvant therapy. Cancer 2002;94:344–51. © 2002 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition to SFK activity and CRC progression, SFK activity has been reported as a marker of poor clinical prognosis (Aligayer et al., 2002).”
From Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab (2011) · cites this paper as Aligayer et al., 2002
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, aberrant SRC activation has been associated with a more aggressive phenotype and a worse prognosis in CRC patients [27, 28].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [28]
The cited source says what the claim attributes to it.
In the citing paper
“Aberrant SRC activation has been associated with a more aggressive phenotype and a worse prognosis in CRC patients [27, 28, 39].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [28]
In the citing paper
“and increased c-Src levels correlate with worse patient survival [13].”
From Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src (2016) · cites this paper as [13]
In the citing paper
“c-src high activity was proved to be correlated with dismal survival, emerging as an independent aggravating prognostic factor.14”
From The molecular rationale of Src inhibition in colorectal carcinomas (2014) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Classification and Regression Trees.
Gordon, A. D., Breiman, L., Friedman, J. H., Olshen, R. A., & Stone, C. J. (1984) · Biometrics · doi:10.2307/2530946 · Cited by 23,867
Classification and Regression Trees.
Ryzin, J. V., Breiman, L., Friedman, J. H., Olshen, R. A., & Stone, C. J. (1986) · Journal of the American Statistical Association · doi:10.2307/2288003 · Cited by 21,030
BMDP Statistical Software 1981.
Bubolz, T. A., & Dixon, W. J. (1984) · Journal of the American Statistical Association · doi:10.2307/2288308 · Cited by 5,231
CELLULAR FUNCTIONS REGULATED BY SRC FAMILY KINASES
Thomas, S. Μ., & Brugge, J. S. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.513 · Cited by 2,537
Spiess, P. E., Lee, A. K., Leibovici, D., Wang, X., Do, K.-A., & Pisters, L. L. (2006) · Cancer · doi:10.1002/cncr.21979 · Cited by 1,930
Molecular themes in oncogenesis
Bishop, J. M. (1991) · Cell · doi:10.1016/0092-8674(91)90636-d · Cited by 1,629
Activating SRC mutation in a subset of advanced human colon cancers
Irby, R. B., Mao, W., Coppola, D., Kang, J., Loubeau, J. M., Trudeau, W., Karl, R., Fujita, D. J., Jove, R., & Yeatman, T. J. (1999) · Nature Genetics · doi:10.1038/5971 · Cited by 489
Flagged first, then by citations
Research works printed but not linked: 2
- Talamonti MS, 1991, The c‐src oncogene participates in the development of human colorectal liver metastases, Surg Forum, 42, 422
- DixonWJ BrownMB EngelmanL. BMDP statistical software. University of California Press 1995.
Cited by
Sorted by citations
Items 201–254 of 254
Targeting Promoter Quadruplex Nucleic Acids for Cancer Therapy
Paulo, A., Castillo, C. C., & Neidle, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12397-2 · Cited by 7
Tyrosine Kinase Inhibitors and Cancer Therapy
Madhusudan, S., & Ganesan, T. S. (2007) · Springer eBooks · doi:10.1007/978-3-540-31209-3_3 · Cited by 6
TOKATLI, Z. F., Türe, M., Ömürlü, İ. K., Coşar, R., & Uzal, M. C. (2011) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-0909-257 · Cited by 6
Src-signaling interference impairs the dissemination of blood-borne tumor cells
Siemann, D. W., Dong, M., Pampo, C., & Shi, W. (2012) · Cell and Tissue Research · doi:10.1007/s00441-012-1415-7 · Cited by 5
Rotert, J. V., Leupold, J. H., Hohenberger, P., Nowak, K., & Allgayer, H. (2014) · Journal of Surgical Oncology · doi:10.1002/jso.23544 · Cited by 5
Self-citationTokuhisa, Y., Lidsky, M. E., Toshimitsu, H., Turley, R. S., Beasley, G. M., Ueno, T., Sharma, K., Augustine, C. K., & Tyler, D. S. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3387-6 · Cited by 5
QSAR models for 1,2,4-benzotriazines as Src inhibitors based on Monte Carlo method
Toropov, A. A., Veselinović, J. B., Veselinović, A. M., Miljković, F. N., & Toropova, A. P. (2014) · Medicinal Chemistry Research · doi:10.1007/s00044-014-1132-8 · Cited by 5
Matthews, D. J., & Gerritsen, M. E. (2010) · Wiley eBooks · doi:10.1002/9780470555293.ch4 · Cited by 5
New approaches and targets in advanced colorectal cancer
Macarulla, T. M., Capdevila, J., Pérez-García, J. M., Ramos, F. J., Élez, E., Markman, B., Ruiz-Echarri, M., & Tabernero, J. M. (2009) · European Journal of Cancer · doi:10.1016/s0959-8049(09)70019-x · Cited by 4
Mucosal Restitution and Repair
Polk, D. B., & Frey, M. R. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382026-6.00042-7 · Cited by 6
The Role of EGFR Inhibition in Colorectal Cancer
Shalan, N., & Hoff, P. M. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-215-1_6 · Cited by 4
Dynamic Regulation of Adherens Junctions: Implication in Cell Differentiation and Tumor Development
Pelissier-Rota, M. A., Chartier, N. T., & Jacquier‐Sarlin, M. R. (2015) · Springer eBooks · doi:10.1007/978-94-017-7380-5_4 · Cited by 3
Kim, S. J., Noh, T. H., Son, S., Kim, D. H., Kim, W., Lee, Y., Choo, J., Heo, G., Kim, M. J., Chung, H. Y., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0942-x · Cited by 3
Kuga, T., Yamane, Y., Hayashi, S., Taniguchi, M., Yamaguchi, N., & Yamagishi, N. (2020) · Scientific Reports · doi:10.1038/s41598-020-64624-x · Cited by 3
Lund, S. C., Brábek, J., & Hanks, S. K. (2008) · Molecular Carcinogenesis · doi:10.1002/mc.20466 · Cited by 3
Biological agents versus chemotherapy in the treatment of colorectal cancer
Eng, C., & Shalan, N. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.10.1251 · Cited by 3
Targeted Therapy in Colorectal Cancer
Kopetz, S. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-424-1_6 · Cited by 3
Src as a Target for Pharmaceutical Intervention
Šuša, M., Missbach, M., Gamse, R., Kneissel, M., Buhl, T., Gasser, J. A., Glatt, M., O’Reilly, T., Teti, A. M., & Green, J. (2006) · Humana Press eBooks · doi:10.1385/1-59259-962-1:071 · Cited by 3
Lipid-driven Src self-association modulates its transformation capacity
Mohammad, I.-L., Giannotti, M. I., Fourgous, E., Boublik, Y., Fernández, A., Roux, A. L., Sirvent, A., Taulés, M., Roche, S., & Pons, M. (2025) · Life Science Alliance · doi:10.26508/lsa.202403019 · Cited by 2
Role of PTPRT in obesity and its substrate paxillin tyrosine-88 in colorectal cancer
Scott, A. J. (2014) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 2
Molecular and biological interactions in colorectal cancer
de Heer, P. (2007) · Cited by 2
Src kinase: a therapeutic opportunity in endocrine-responsive and resistant breast cancer
Hiscox, S., & Nicholson, R. I. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.29 · Cited by 2
Advances in targeted therapies for metastatic colorectal cancer
Pérez-García, J. M., Capdevila, J., Macarulla, T. M., Ramos, F. J., Élez, E., Ruiz-Echarri, M., & Tabernero, J. M. (2009) · Therapy · doi:10.2217/thy.09.11 · Cited by 2
Molecular staging of cancer: Concepts of today, therapies of tomorrow
Allgayer, H. (2003) · Journal of Surgical Oncology · doi:10.1002/jso.10226 · Cited by 2
Self-citationMohammad, I.-L., Carvajal, J., Fernández, A., Taulés, M., Fourgous, E., Boublik, Y., Roux, A. L., Roche, S., & Pons, M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.31.494233 · Cited by 2
Tian, M., Zhang, S., Li, Y., & Fengi, B. (2024) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm62325.2024.10822435 · Cited by 1
Mortlock, A. A., & Barker, A. J. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00209-1 · Cited by 1
Mucosal Repair and Restitution
Frey, M. R., & Polk, D. B. (2006) · Elsevier eBooks · doi:10.1016/b978-012088394-3/50019-2 · Cited by 1
Bourdeanu, L., Liu, E. Y., Brint, S., & Langdon, D. E. (2017) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-70142-4_4 · Cited by 1
Wang, H., Chen, X., Bao, L., & Zhang, X. (2020) · Medicine · doi:10.1097/md.0000000000022199 · Cited by 1
Therapeutic Effects of Curcumin Against Colorectal Cancer
Lambring, C. B., Shelake, S., Hasan, F., & Basha, R. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-48405-7_10 · Cited by 1
The role of E-cadherin in colon cancer drug resistance.
Murray, L. J. (2010) · Enlighten: Theses (The University of Glasgow) · Cited by 1
Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitorsPreprint
Dawson, J. C., Munro, A. F., Macleod, K., Muir, M., Timpson, P., Williams, R. J., Frame, M. C., Brunton, V. G., & Carragher, N. O. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.27.457893 · Cited by 1
A Role For Lipid Rafts In Egfr Tki Resistance In Breast Cancer
Irwin, M. E. (2010) · Human Biology
The Crucial Role of c-Src Tyrosine Kinase in Bone Metabolism
Peruzzi, B., Rucci, N., & Teti, A. M. (2012) · InTech eBooks · doi:10.5772/37995
Characterization of Jak, STAT, and Src interactions in Head and Neck Squamous Cell Carcinoma
Jaseja, R. (2013) · Digital Commons-TMC (Texas Medical Center)
IGF-1R : Studies on the expression and role in transformation
Natalishvili, N. (2009) · Figshare
Molecular Targeting of Colorectal Cancer
Sundermeyer, M. L., Bellacosa, A., & Meropol, N. J. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-337-0_7
The role of Src kinase in renal cell carcinoma
Qayyum, T. (2014) · Enlighten: Theses (The University of Glasgow)
Regulation of Breast Cancer Stem Cell by Tissue Rigidity
Engler, A. J., Yang, J., Wei, S. C., Fattet, L., & Ondeck, M. G. (2014) · Defense Technical Information Center (DTIC) · doi:10.21236/ada609393
SRC (v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian))
Hiscox, S. (2011) · Atlas of Genetics and Cytogenetics in Oncology and Haematology · doi:10.4267/2042/44715
Garcia, C. M., & Gutmann, D. H. (2014) · Scientifica · doi:10.1155/2014/915725
Dissection of α6β4 Integrin-Dependent Signaling and Breast Carcinoma Invasion: A Dissertation
Yang, X. (2011) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/k2m9-am39
A move towards individualization of patient treatment regimens in colorectal cancer
Powell, A. G. M. T., Edwards, J., & Horgan, P. G. (2011) · Colorectal Disease · doi:10.1111/j.1463-1318.2011.02818.x
Investigations into the Interaction between Src Kinase and Wnt Signaling
Tang, P. L. (2009) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/14854
Lipid-driven SRC self-association modulates its transformation capacityPreprint
Mohammad, I.-L., Giannotti, M. I., Fourgous, E., Boublik, Y., Fernándz, A., Roux, A. L., Sirvent, A., Taulés, M., Roche, S., & Pons, M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.12.623151
Nonreceptor Tyrosine Kinases and Their Roles in Cancer
Wiener, J. R., & Gallick, G. E. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1216-8_4
Self-citationDevelopment of novel therapies for colorectal carcinoma using dietary indoles
Brookes, A. (2014) · Leicester Research Archive (University of Leicester)
Metadata
- Authors
- Allgayer, H., Boyd, D. D., Heiss, M. M., Abdalla, E. K., Curley, S. A., & Gallick, G. E.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Gallick, Gary E.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2002-01-15
- Volume
- 94
- Issue
- 2
- Pages
- 344-351
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1532635242
- Cited by
- 251
- References
- 51
- Citations by year
- 2025: 3 · 2024: 3 · 2023: 1 · 2022: 4 · 2021: 7 · 2020: 9 · 2019: 11 · 2018: 7 · 2017: 9 · 2016: 11 · 2015: 14 · 2014: 16 · 2013: 16 · 2012: 13
- FWCI
- 5.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Gillson Longenbaugh Foundation
- Deutsche Krebshilfe
- National Institutes of Health (5r01ca065527-07)
- National Cancer Institute (CA65527, CA69926, CA53617, CA 58311)
- National Institute of Dental and Craniofacial Research (DE10845, R01DE010845)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- Src kinase, colorectal cancer, prognostic factors, urokinase-type plasminogen activator receptor, non-receptor tyrosine kinase, overall survival, disease-free survival, Dukes stage, adjuvant therapy selection, Src kinase inhibitor, metastasis
- MeSH terms
- CSK Tyrosine-Protein Kinase, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Enzyme Activation, Female, Humans, Male, Middle Aged, Mucous Membrane, Protein-Tyrosine Kinases, Receptors, Cell Surface, Colorectal Neoplasms, Survival Rate, src Homology Domains, src-Family Kinases, Receptors, Urokinase Plasminogen Activator
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
